Form 4: CEO Jack Bendheim's Entity Sells PAHC Shares

An entity controlled by Phibro Animal Health CEO Jack Bendheim converted Class B shares to Class A and subsequently sold a portion of Class A common stock.

Summary

• Jack Bendheim, President and CEO, and a 10% owner of Phibro Animal Health Corp (PAHC), along with BFI Co., LLC (also a 10% owner), filed a Form 4.
• On March 12, 2026, BFI Co., LLC converted 100,000 shares of Class B Common Stock into 100,000 shares of Class A Common Stock.
• On March 13, 2026, BFI Co., LLC sold 5,280 shares of Class A Common Stock at a weighted average price of $48.91 per share.
• These sales were executed under a Rule 10b5-1 trading plan adopted on December 11, 2025.
• Following these transactions, BFI Co., LLC indirectly holds 96,200 Class A Common Stock and 19,596,034 Class B Common Stock (which are convertible to Class A).
• Jack Bendheim directly holds 16,840 Class A Common Stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the insider sale by a key executive's entity, though the impact is somewhat mitigated by the pre-arranged 10b5-1 trading plan.

Negatives

• An entity controlled by the CEO and 10% owner sold 5,280 shares of Class A Common Stock.

Risks

• Potential negative market perception due to insider selling, even if pre-planned under a Rule 10b5-1 plan.

Future Outlook

NA

Management Comments

• NA

Industry Context

StockSavvy.ai notes that insider sales, even those executed under a pre-arranged 10b5-1 plan, are often scrutinized by investors for potential signals regarding management's confidence in the company's future prospects. While the sale is relatively small compared to the total holdings, it represents a reduction in direct equity exposure by a key executive and significant shareholder.

Related Party Transactions

• The transactions involve Jack Bendheim, President and CEO and a 10% owner, and BFI Co., LLC, also a 10% owner, over which Mr. Bendheim exercises voting and dispositive power, indicating a related party dealing.

Stakeholder Impact

• Shareholders may interpret the insider sale as a lack of confidence, potentially leading to negative sentiment or downward pressure on the stock price.

Next Steps

• NA

Key Dates

Recommendation

The sale of shares by an entity controlled by the CEO and a 10% owner, even under a pre-arranged 10b5-1 plan, can be viewed as a slight negative signal by the market. However, the volume of shares sold is not exceptionally large relative to total holdings, and the pre-planned nature mitigates some of the immediate negative implications. Investors should monitor future insider activity and company performance, maintaining a 'hold' position based solely on this filing.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Class A Common Stock, Class B Common Stock